Similarly, KRAS mutations, another prominent genetic alteration in CRC, can lead to increased expression of CXCL3, thereby enhancing the migration of CXCR2+ MDSCs and fostering resistance to anti-PD-1 immunotherapy [15]. This evidence concerns the gene KRAS and colorectal carcinoma.